-
公开(公告)号：US20180030544A1
公开(公告)日：2018-02-01
申请号：US15651652
申请日：2017-07-17
Applicant: Myriad Genetics, Inc.
Inventor： Victor Abkevich , Kirsten Timms , Alexander Gutin
CPC classification number: C12Q1/6886 , A61K33/24 , C12Q1/6827 , C12Q1/6858 , C12Q2600/106 , C12Q2600/154 , C12Q2600/156 , G16B20/00 , C12Q2535/122 , C12Q2537/143
Abstract: This document provides methods and materials involved in assessing samples (e.g., cancer cells) for the presence of homologous recombination deficiency (HRD) or an HRD signature. For example, methods and materials for determining whether or not a cell (e.g., a cancer cell) contains an HRD signature are provided. Materials and methods for identifying cells (e.g., cancer cells) having a deficiency in homology directed repair (HDR) as well as materials and methods for identifying cancer patients likely to respond to a particular cancer treatment regimen also are provided.
-
公开(公告)号：US09388472B2
公开(公告)日：2016-07-12
申请号：US14307708
申请日：2014-06-18
Applicant: Myriad Genetics, Inc.
Inventor： Victor Abkevich , Alexander Gutin , Kirsten Timms , Jerry Lanchbury
IPC: C12Q1/68
CPC classification number: C12Q1/6886 , A61K31/282 , A61K33/24 , C12Q2600/106 , C12Q2600/154 , C12Q2600/156 , C12Q2600/158
Abstract: This document provides methods and materials involved in assessing samples (e.g., cancer cells) for the presence of a loss of heterozygosity (LOH) signature. For example, methods and materials for determining whether or not a cell (e.g., a cancer cell) contains an LOH signature are provided. Materials and methods for identifying cells (e.g., cancer cells) having a deficiency in homology directed repair (HDR) as well as materials and methods for identifying cancer patients likely to respond to a particular cancer treatment regimen also are provided.
Abstract translation: 本文件提供了评估样品（例如癌细胞）中存在杂合性（LOH）特征丧失的方法和材料。 例如，提供了用于确定细胞（例如，癌细胞）是否包含LOH标记的方法和材料。 还提供了用于鉴别具有同源性定向修复（HDR）缺陷的细胞（例如癌细胞）的材料和方法以及用于鉴定可能对特定癌症治疗方案作出反应的癌症患者的材料和方法。
-
公开(公告)号：US20150344966A1
公开(公告)日：2015-12-03
申请号：US14721824
申请日：2015-05-26
Applicant: Myriad Genetics, Inc.
Inventor： Kirsten Timms , Brian Allen , Anne-Renee Hartman
IPC: C12Q1/68
CPC classification number: C12Q1/6886 , C12Q2600/118
Abstract: The disclosure generally relates to a molecular classification of disease predisposition and particularly to molecular markers for cancer predisposition and methods of use thereof.
Abstract translation: 本公开一般涉及疾病易感性的分子分类，特别涉及用于癌症倾向的分子标记及其使用方法。
-
公开(公告)号：US20140162886A1
公开(公告)日：2014-06-12
申请号：US14109163
申请日：2013-12-17
Applicant: Myriad Genetics, Inc.
Inventor： Alexander Gutin , Kirsten Timms , Jerry Lanchbury
CPC classification number: C12Q1/6827 , C12Q1/6858 , C12Q1/6874 , C12Q1/6883 , G06F19/22 , C12Q2535/122 , C12Q2537/143
Abstract: Methods and systems for detecting allelic imbalance using nucleic acid sequencing are provided.
Abstract translation: 提供了使用核酸测序检测等位基因不平衡的方法和系统。
-
公开(公告)号：US20230111438A1
公开(公告)日：2023-04-13
申请号：US18081586
申请日：2022-12-14
Applicant: Myriad Genetics, Inc.
Inventor： Victor Abkevich , Alexander Gutin , Kirsten Timms , Jerry Lanchbury
IPC: C12Q1/6886 , G16B20/20 , G16B20/10 , A61K33/243 , A61K31/282
Abstract: This document provides methods and materials involved in assessing samples (e.g., cancer cells) for the presence of a loss of heterozygosity (LOH) signature. For example, methods and materials for determining whether or not a cell (e.g., a cancer cell) contains an LOH signature are provided. Materials and methods for identifying cells (e.g., cancer cells) having a deficiency in homology directed repair (HDR) as well as materials and methods for identifying cancer patients likely to respond to a particular cancer treatment regimen also are provided.
-
Patent Agency Ranking
公开(公告)号：US20220205046A1
公开(公告)日：2022-06-30
申请号：US17499284
申请日：2021-10-12
Applicant: Myriad Genetics, Inc.
Inventor： Victor Abkevich , Alexander Gutin , Kirsten Timms , Jerry Lanchbury
IPC: C12Q1/6886 , C12Q1/6827 , G16B20/00 , G16H20/00 , G16B20/20 , G16B20/10
Abstract: This document provides methods and materials involved in assessing samples (e.g., cancer cells) for the presence of a loss of heterozygosity (LOH) signature. For example, methods and materials for determining whether or not a cell (e.g., a cancer cell) contains an LOH signature are provided. Materials and methods for identifying cells (e.g., cancer cells) having a deficiency in homology directed repair (HDR) as well as materials and methods for identifying cancer patients likely to respond to a particular cancer treatment regimen also are provided.
-
公开(公告)号：US11174519B2
公开(公告)日：2021-11-16
申请号：US16691480
申请日：2019-11-21
Applicant: MYRIAD GENETICS, INC.
Inventor： Victor Abkevich , Alexander Gutin , Kirsten Timms , Jerry Lanchbury
IPC: C12Q1/6886 , C12Q1/6827 , G16B20/00 , G16H20/00 , G16B20/20 , G16B20/10
Abstract: This document provides methods and materials involved in assessing samples (e.g., cancer cells) for the presence of a loss of heterozygosity (LOH) signature. For example, methods and materials for determining whether or not a cell (e.g., a cancer cell) contains an LOH signature are provided. Materials and methods for identifying cells (e.g., cancer cells) having a deficiency in homology directed repair (HDR) as well as materials and methods for identifying cancer patients likely to respond to a particular cancer treatment regimen also are provided.
-
公开(公告)号：US11104956B2
公开(公告)日：2021-08-31
申请号：US14561938
申请日：2014-12-05
Applicant: Myriad Genetics, Inc.
Inventor： Kirsten Timms , Brian Allen , Anne-Renee Hartman
IPC: C12P19/34 , C12Q1/6886 , G01N33/574 , G16B20/00 , A61K31/138 , G16B30/00
Abstract: The invention generally relates to a molecular classification of disease predisposition and particularly to molecular markers for cancer predisposition and methods of use thereof.
-
公开(公告)号：US10851425B2
公开(公告)日：2020-12-01
申请号：US16576643
申请日：2019-09-19
Applicant: MYRIAD GENETICS, INC.
Inventor： Victor Abkevich , Alexander Gutin , Kirsten Timms , Jerry Lanchbury
IPC: C12Q1/6886 , C12Q1/6827 , G16B20/00
Abstract: This document provides methods and materials involved in assessing samples (e.g., cancer cells) for the presence of a loss of heterozygosity (LOH) signature. For example, methods and materials for determining whether or not a cell (e.g., a cancer cell) contains an LOH signature are provided. Materials and methods for identifying cells (e.g., cancer cells) having a deficiency in homology directed repair (HDR) as well as materials and methods for identifying cancer patients likely to respond to a particular cancer treatment regimen also are provided.
-
公开(公告)号：US10400287B2
公开(公告)日：2019-09-03
申请号：US15433249
申请日：2017-02-15
Applicant: Myriad Genetics, Inc.
Inventor： Victor Abkevich , Kirsten Timms , Alexander Gutin , Julia Reid
IPC: C12Q1/68 , C12Q1/6886
Abstract: This document provides methods and materials involved in assessing samples (e.g., cancer cells) for the presence of homologous recombination deficiency (HRD) or an HRD signature. For example, methods and materials for determining whether or not a cell (e.g., a cancer cell) contains an HRD signature are provided. Materials and methods for identifying cells (e.g., cancer cells) having a deficiency in homology directed repair (HDR) as well as materials and methods for identifying cancer patients likely to respond to a particular cancer treatment regimen also are provided.
-
-
-
-
-
-
-
-
-
Search Results
33
records
(took 0.051 seconds)
